RE:RE:RE:RE:urokinase other possible benifitsIs this the phrase that you say ".....sound fairly generic."?
Page 6 of their MD&A states: In December of 2013 Microbix’ license partner, Zydus, advised Microbix that it is terminating the Kinlytic license agreement due to a change in their strategic priorities. Management is in discussion with various interested parties and will provide an update in the second quarter of fiscal 2014.
I appreciate your history here and the background you provided on Urikonase; but think you might be a bit too pessimistic about the prospects for it. Given the statement above rom their MD&A, I personally think they have a good chance of finding a stronger partner bound by a more definitive agreement than they had with Zydus, one with more specific development milestones and performance gaurantees (one should hope the new management won't sign such an open-ended agreement with their next partner).
Getting a bit more speculative, given the research on Urokinase we have been finding from academic researchers, I suspect we might find a partner not just interested in resurrecting it for it's old uses, but for expanding R&D for it's use in new applications and treatments.
The second quarter ends in a little more than a month, I look forward to the "update" to see who is more on target with their expectations. :)